To the Editor:

Banerji et al. describe the allergy assessment of 123 patients who had perioperative allergic reactions, including the experience of those who went on to have subsequent anesthesia after their allergy evaluation. The authors note that their diagnostic testing expanded over time and that they identified new causative agents. Although they mention blue dye among other new potential culprits for perioperative allergic reactions, their series identified no patients where this was the identified allergen. We have identified isosulfan blue as the agent responsible for perioperative allergic reactions in 3 patients over only the last 6 months (Table I) and suspect that this allergy may be more common than realized. All 3 patients went on to uneventful subsequent surgery with exposure to the same medications except isosulfan blue (and in one case also ondansetron).

At our institution, we follow a similar approach as that described by Banerji et al, carefully examining the anesthesia record for all medications administered before the onset of symptoms suggestive of an allergic or anaphylactic reaction and also evaluating substances to which the patient may have been exposed but that are not specifically mentioned, such as latex. However, isosulfan blue is not listed on the anesthesia record because it is not administered by the anesthesiologist. Instead, its administration is described in the operative report, because it is not administered by the anesthesiologist. For this reason, its administration may be overlooked, and it may thus be responsible for some of the cases where no culprit allergen is identified.

The package insert for isosulfan blue states, “Case series report an overall incidence of hypersensitivity reactions in approximately 2% of patients. Life-threatening anaphylactic reactions have occurred. Manifestations include respiratory distress, shock, angioedema, urticaria, pruritus” (isosulfan blue injection, solution; Mylan Institutional LLC, Morgantown, WV). Of 2392 sequential patients who underwent sentinel lymph node mapping for breast cancer involving isosulfan blue dye at a single institution, 1.6% had a documented allergic reaction; most involved urticaria, but the incidence of hypotensive reactions was 0.5%. A recent meta-analysis estimated the rate of anaphylaxis with all blue dyes, including isosulfan blue, patent blue, and methylene blue, to be 0.061%, noting a higher rate with breast cancer surgery (0.083%) and a higher rate with isosulfan blue (0.160%) compared with patent blue (0.05%) and methylene blue (0.0006%). The lower rates in the meta-analysis may be due to exclusion of case series and lower grades of anaphylaxis.

Most reactions to isosulfan blue occur on first exposure. It has been hypothesized that sensitization may occur through prior exposure to patent blue and other structurally related triaryl methane dyes used in textiles, cosmetics, and medications. Cross-reactivity between isosulfan blue and patent blue has been reported. Should a patient who has had an allergic reaction to isosulfan blue require a dye in the future, methylene blue, which is not structurally related to isosulfan blue or patent blue, may be considered.

In evaluating perioperative allergic reactions, we recommend careful scrutiny not only of the anesthesia record but also the

### TABLE I. Patients with isosulfan blue–induced intraoperative systemic allergic reactions

<table>
<thead>
<tr>
<th>Age</th>
<th>Sex</th>
<th>Type of surgery</th>
<th>Symptoms</th>
<th>Treatment for allergic reaction</th>
<th>Isosulfan blue skin test results (millimeter wheal/millimeter erythema)</th>
<th>Skin test results (millimeter wheal/millimeter erythema) for other substances given before reaction</th>
<th>Outcome of subsequent surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>Female</td>
<td>Mastectomy</td>
<td>Flushing, hypotension (systolic 60s)</td>
<td>Ephedrine, phenylephrine, epinephrine, diphenhydramine</td>
<td>Prick 10 mg/mL (1%): 0; Cefazolin, dexamethasone, fentanyl, midazolam, propofol: negative</td>
<td></td>
<td>Uneventful despite receipt of cefazolin, dexamethasone, fentanyl, midazolam, propofol</td>
</tr>
<tr>
<td>40</td>
<td>Female</td>
<td>Mastectomy</td>
<td>Hypotensive (50s-60s/30s, refractory to multiple doses of phenylephrine), low O2 saturation (80%)</td>
<td>Phenylephrine, diphenhydramine, methylprednisolone</td>
<td>Prick 10 mg/mL (1%): 5/40; intradermal: not done</td>
<td></td>
<td>Uneventful despite receipt of cefazolin, dexamethasone, fentanyl, metoclopramide, propofol: negative; ondansetron prick full strength 0, intradermal 1:100 9/22</td>
</tr>
<tr>
<td>64</td>
<td>Female</td>
<td>Mastectomy</td>
<td>Flushing, hives</td>
<td>Ephedrine, phenylephrine, diphenhydramine</td>
<td>Prick 10 mg/mL (1%): 5/8; intradermal 1 mg/mL (0.1%): 10/15</td>
<td></td>
<td>Uneventful despite receipt of cefazolin, dexamethasone, fentanyl, midazolam, propofol</td>
</tr>
</tbody>
</table>
operative notes, and also consideration of isosulfan blue as a potential culprit.

John M. Kelso, MD

Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, Calif.

No funding was received for this work.

Conflicts of interest: The author declares that he has no relevant conflicts of interest.

Received for publication June 2, 2021; accepted for publication June 28, 2021.

Corresponding author: John M. Kelso, MD, Scripps Clinic, 3811 Valley Centre Drive, San Diego, CA 92130. E-mail: kelso.john@sc rpipshealth.org.

REFERENCES


https://doi.org/10.1016/j.jaip.2021.07.052

Reply to “Isosulfan blue-induced perioperative systemic allergic reactions”

To the Editor:

We thank Dr Kelso for his correspondence1 to our article “Perioperative allergic reactions: allergy assessment and subsequent anesthesia” in the Journal of Allergy and Clinical Immunology: In Practice.2

Blue dyes including methylene blue, patent blue, and isosulfan blue are used clinically to identify sentinel lymph nodes in patients undergoing oncologic evaluations. A recent meta-analysis describes a 0.06% anaphylaxis rate to blue dyes, whereas another single-center study describes hypotension on 0.5% of cases using isosulfan blue dye. Overall, blue dyes are indeed being increasingly identified as “hidden” causative agents of perioperative allergic reactions,3,4 and allergists should include them in the list of possible causative agents when evaluating patients with perioperative allergic reactions. Allergists can also perform dye skin testing using the published nonirritating skin testing concentrations as part of the comprehensive evaluation in cases where dyes were used.5,6

We agree that a thorough review of the electronic medical records including the anesthesia record and operative report is needed as part of the allergy consultation and assessment. At our academic medical center, we also review the operating room nursing record, which may document irrigations such as heparin and saline mixture, bacitracin and saline mixture, and Visipaque dye given intra-arterially. Lastly, a comprehensive approach to perioperative allergic reactions should include review of the medication administration report where all agents given during a procedure should be thoroughly documented.

Aleena Banerji, MD

Kimberly G. Blumenthal, MD, MS

1Division of Rheumatology Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass
2Harvard Medical School, Boston, Mass
3Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, Mass

No funding was received for this work.

Conflicts of interest: The author declares that he has no relevant conflicts of interest.

Received for publication June 25, 2021; accepted for publication June 28, 2021.

Corresponding author: Aleena Banerji, MD, Massachusetts General Hospital, Cox 210, 100 Blossom Street Boston MA 02114. E-mail: abanerji@mgh.harvard.edu.

REFERENCES


https://doi.org/10.1016/j.jaip.2021.06.052

The allergic effector unit: From basic science to drug-targetable mast cell–eosinophil interactions in patients

To the Editor:

We read with great interest Guillet et al’s Clinical Communication1 presenting the effect of mepolizumab administration in an eosinophilic bronchial asthma patient with concomitant idiopathic mast cell (MC) activation syndrome. The authors found that mepolizumab administration resulted in a reduction of blood eosinophilia, eosinophilic cationic protein (ECP), and serum tryptase levels, with amelioration of asthma, gut, and skin symptoms. Interestingly, although both omalizumab and mepolizumab reduced serum tryptase, only the latter decreased asthma symptoms. This is possibly due to omalizumab binding to circulating free IgE, thus not affecting already bound IgE.2

The reduction in tryptase and ECP serum levels might be due to a direct effect of mepolizumab on MCs. It was published that administration of mepolizumab in pediatric eosinophilic esophagitis significantly reduced MC numbers and occurrence of MC-eosinophils (Eos) couples due to inhibition of IL-9 production from Eos, thus influencing MC survival in the gut.3 Mepolizumab can affect the Eos, which, when not inhibited, engage MCs in a physical and soluble crosstalk we named allergic effector unit (AEU). Indeed, in previous works, we showed that the activating receptor CD48 on human cord blood-derived MCs engages CD244/2B4 on peripheral blood Eos, resulting in activation of both cells.4 Importantly, MCs and Eos produce several mediators...